Pirenzepine ophthalmic - Novartis
Alternative Names: PIR 335; Pirenzepine ophthalmic gelLatest Information Update: 05 May 2008
At a glance
- Originator Valley Forge Pharmaceuticals
- Developer Novartis Ophthalmics
- Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Piperazines; Pyridones; Small molecules
- Mechanism of Action Muscarinic M1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Myopia
Most Recent Events
- 05 May 2008 Discontinued - Phase-II for Myopia in Hong Kong (Ophthalmic)
- 05 May 2008 Discontinued - Phase-II for Myopia in Singapore (Ophthalmic)
- 05 May 2008 Discontinued - Phase-II for Myopia in Thailand (Ophthalmic)